Cargando…
(−)-Kusunokinin as a Potential Aldose Reductase Inhibitor: Equivalency Observed via AKR1B1 Dynamics Simulation
[Image: see text] (−)-Kusunokinin performed its anticancer potency through CFS1R and AKT pathways. Its ambiguous binding target has, however, hindered the next development phase. Our study thus applied molecular docking and molecular dynamics simulation to predict the protein target from the pathway...
Autores principales: | Tanawattanasuntorn, Tanotnon, Thongpanchang, Tienthong, Rungrotmongkol, Thanyada, Hanpaibool, Chonnikan, Graidist, Potchanapond, Tipmanee, Varomyalin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807751/ https://www.ncbi.nlm.nih.gov/pubmed/33458512 http://dx.doi.org/10.1021/acsomega.0c05102 |
Ejemplares similares
-
Trans-(−)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?
por: Rattanaburee, Thidarath, et al.
Publicado: (2021) -
Trans-(±)-Kusunokinin Binding to AKR1B1 Inhibits Oxidative Stress and Proteins Involved in Migration in Aggressive Breast Cancer
por: Tanawattanasuntorn, Tanotnon, et al.
Publicado: (2022) -
Potential Stereoselective Binding of Trans-(±)-Kusunokinin and Cis-(±)-Kusunokinin Isomers to CSF1R
por: Chompunud Na Ayudhya, Chompunud, et al.
Publicado: (2022) -
Effects of trans-(±)-kusunokinin on chemosensitive and chemoresistant ovarian cancer cells
por: Mad-Adam, Nadeeya, et al.
Publicado: (2022) -
Anticancer Activity of (±)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells
por: Rattanaburee, Thidarath, et al.
Publicado: (2022)